CardioMed Client Accepted into FDA TAP Pilot

After receiving Breakthrough Device Designation earlier in the year, a CardioMed client was accepted into the FDA program, TPLC Advisory Program Pilot (“TAP Pilot”).
The purpose of TAP Pilot is to “spur more rapid development of high-quality, safe, effective, and innovative medical devices that are critical to public health” (Total Product Life Cycle Advisory Program (TAP) | FDA). This is a great opportunity for CardioMed and the client to work closely with FDA TAP Team to learn first-hand how Breakthrough Device Designation and TAP programs can expedite patent access to novel cardiovascular devices.